NeuroSense Therapeutics (NASDAQ:NRSN) Receives “Hold” Rating from Maxim Group

Maxim Group reaffirmed their hold rating on shares of NeuroSense Therapeutics (NASDAQ:NRSN) in a research report released on Monday,Benzinga reports.

NeuroSense Therapeutics Trading Up 2.8 %

Shares of NeuroSense Therapeutics stock opened at $0.88 on Monday. The business’s fifty day simple moving average is $1.12 and its 200 day simple moving average is $1.03. NeuroSense Therapeutics has a 12 month low of $0.51 and a 12 month high of $2.33. The firm has a market capitalization of $12.08 million, a P/E ratio of -1.04 and a beta of 1.38.

Institutional Investors Weigh In On NeuroSense Therapeutics

An institutional investor recently bought a new position in NeuroSense Therapeutics stock. Armistice Capital LLC bought a new position in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 1,584,000 shares of the company’s stock, valued at approximately $1,774,000. Armistice Capital LLC owned approximately 11.59% of NeuroSense Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.